Resource Library
Showing 201 to 210 of 330 results
Image
In this presentation, Dr. Mahmoud Elsawy, hematologist and medical director of IEC (CAT T) Therapy at the Nova Scotia Health Authority talked about the first CAR T-cell therapy program in Atlantic Canada. Dr. Elsawy, reviewed how the program came to Atlantic Canada, what patients can expect today and what we can expect in the future.
Image
Whether you are thinking about or planning a return, already back at it or wanting to take your career or education in a new direction, this webcast will help you think through the big and small issues that may arise. Following the presentation, you will hear from adolescent and young adult survivors on their first-hand experiences.
Image
For some children and teens, emotional and cognitive challenges continue or become evident after treatment ends. How do we recognize these challenges and help ensure these children and teens receive the support they need?
Image
Learn more about the fear of recurrence.
Image
This factsheet is for children, teens, and young adults who have been affected by a blood cancer, as well as their families. It promotes an active, safe, and adapted lifestyle during and after treatment.
Image
A short video describing treatment options for CLL
Image
In this animated video, the character talks about the side effects after cancer treatment, especially fatigue and brain fog, and gives suggestions for managing them on a daily basis.
Image
In this animated video, the character talks about the emotional and psychological impact of the diagnosis on himself and his family, as well as the importance of talking to those around him and to health professionals to find solutions.
Image
Personalized medicine has evolved so much over the past decade. Join Dr. Rauh, an expert in cancer care to learn how biomarker testing is being used to determine the exact profile of a blood cancer, monitor its progression and determine the best treatment option available to someone who is newly diagnosed.
Image
Blood cancer research is constantly progressing. It may be a real challenge to make treatment related decisions when there are many options including late breaking clinical trials.